Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.47 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.47 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.47 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.47 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9083835 | 0.91 | ACLY (0.51) | PDPK1CNR1IDO1HPGDPLAAT3 | |
| SCHEMBL7330078 | 0.86 | PDPK1 (0.56) | PDPK1CNR1IDO1HPGDCYP1A2 | |
| SCHEMBL19612677 | 0.86 | ACLY (0.58) | ACLY | |
| SCHEMBL30567601 | 0.85 | PDPK1 (0.59) | PDPK1CNR1HPGDPLAAT3PLAAT5 | |
| SCHEMBL586345 | 0.85 | PDPK1 (0.59) | PDPK1CNR1HPGDPLAAT3PLAAT5 | |
| SCHEMBL2339040 | 0.83 | PDPK1 (0.54) | PDPK1CNR1IDO1HPGDCYP1A2 | |
| SCHEMBL31346720 | 0.83 | PDPK1 (0.54) | PDPK1CNR1IDO1HPGDCYP1A2 | |
| SCHEMBL5943830 | 0.83 | PDPK1 (0.54) | PDPK1CNR1IDO1HPGDCYP1A2 | |
| SCHEMBL2849945 | 0.83 | PDPK1 (0.54) | PDPK1CNR1IDO1HPGDCYP1A2 | |
| SCHEMBL30799277 | 0.83 | PDPK1 (0.54) | PDPK1CNR1IDO1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756112-B1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| WO-2009141096-A1 | SUBSTITUTED SPIRO-ISOXAZOLINES | BAYER CROPSCIENCE AG (DE) | 2009-11-26 | — | — | WO | disclosed |
| EP-1756112-A1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Boehringer Ingelheim International GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| WO-2005111040-A1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| EP-1598353-A1 | Pyrrolobenzimidazolones and their use as antiproliferative agents | Boehringer Ingelheim International GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| EP-0730454-A4 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO INC (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-0907644-A4 | PHARMACEUTICAL PREPARATION | MERCK & CO INC (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-0907644-A1 | PHARMACEUTICAL PREPARATION | Merck & Co., Inc. (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997049690-A1 | A METHOD FOR TREATING MENIERE'S DISEASE | MERCK & CO., INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| CN-1142184-A | Antiarrhythmic benzodiazepines * | MERCK & CO INC (US) | 1997-02-05 | — | — | CN | disclosed |
| US-5597818-A | CARDIOVASCULAR DISORDERS | MERCK & CO., INC. (US) | 1997-01-28 | — | — | US | disclosed |
| US-5595990-A | TREATMENT OF CARDIOVASCULAR DISORDERS | MERCK & CO., INC. (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0730454-A1 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO. INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0730453-A1 | METHODS OF TREATING CARDIAC ARRHYTHMIA | MERCK & CO. INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5428031-A | Benzodiazepine analogs; cardiovascular disorders | MERCK & CO., INC. (US) | 1995-06-27 | — | — | US | disclosed |
| US-5426185-A | Antiarrhythmia agents having reduced side effects | MERCK & CO., INC. (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1995014471-A1 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1995014470-A1 | METHODS OF TREATING CARDIAC ARRHYTHMIA | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | MKI67, CCNI, CCNA1 | PDPK1 117/4885CNR1 1177/4885IDO1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.